Related Experiment Videos
UCN-01 selectively enhances mitomycin C cytotoxicity in p53 defective cells which is mediated through S and/or G(2)
K Sugiyama1, M Shimizu, T Akiyama
1Pharmaceutical Research Institute, Kyowa Hakko Kogyo Co., Ltd., Shizuoka, Japan.
Abstract:
We have previously reported that UCN-01 (7-hydroxystaurosporine), a protein kinase inhibitor that is under clinical trials as an anti-cancer agent in the USA and Japan, enhanced the anti-tumor activity of mitomycin C (MMC) in vitro and in vivo. Subsequent studies from other laboratories revealed that UCN-01 could selectively enhance cytotoxicity of DNA damaging agents in p53 defective cells and that this was mediated by abrogation of S and /or G(2) arrest by UCN-01. In this study, we report that UCN-01 selectively enhances the cytotoxicity of MMC in human p53 mutant cell lines. In contrast, UCN-01 showed little, if any, effect on MMC cytotoxicity in human p53 wild-type cell lines. Terminal deoxynucleotidyl transferase (TdT)-mediated dUTP-nick end-labeling (TUNEL) assay revealed that the combination of MMC with UCN-01 increased DNA breaks consistent with apoptosis in p53 defective A431 epidermoid carcinoma cells. In p53 wild-type MCF-7 breast carcinoma cells, the cyclin-dependent kinase inhibitor protein p21/WAF1 was markedly induced after the treatment with MMC alone, although this response was significantly delayed from the time of MMC treatment. Detailed cell-cycle studies revealed that UCN-01 abrogated S and G(2) phase accumulation induced by MMC in p53 defective cells and to a lesser extent in p53 wild-type cell lines. The abrogation of arrest in p53 wild-type cells was observed prior to significant induction of the p53 response. Since MMC was less effective against p53 defective cell lines than against p53 wild-type cell lines and UCN-01 selectively enhanced MMC cytotoxicity in p53 defective cell lines, UCN-01 may provide a new modality of MMC-based cancer chemotherapy, particularly in p53 defective cancer patients.
Insights
UCN-01 enhances the anti-cancer drug mitomycin C (MMC) effectiveness, particularly in cancer cells with defective p53. This protein kinase inhibitor may offer new chemotherapy options for patients with p53-mutated tumors.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- UCN-01 (7-hydroxystaurosporine) is a protein kinase inhibitor investigated for anti-cancer properties.
- Previous research indicated UCN-01 enhances anti-tumor activity of mitomycin C (MMC).
- UCN-01 selectively augments cytotoxicity of DNA-damaging agents in p53-defective cells by abrogating cell cycle arrest.
Purpose of the Study:
- To investigate the selective enhancement of mitomycin C (MMC) cytotoxicity by UCN-01 in human p53 mutant cell lines.
- To compare the effect of UCN-01 on MMC cytotoxicity in p53 mutant versus p53 wild-type cell lines.
- To elucidate the role of cell cycle arrest and p53 status in mediating the synergistic effects of UCN-01 and MMC.
Main Methods:
- Utilized human p53 mutant and wild-type cancer cell lines.
- Administered UCN-01 in combination with mitomycin C (MMC).
- Assessed cytotoxicity using TUNEL assay for DNA breaks and apoptosis.
- Performed detailed cell-cycle analysis to evaluate S and G2 phase arrest.
- Monitored p21/WAF1 induction in response to MMC treatment.
Main Results:
- UCN-01 significantly enhanced MMC cytotoxicity in human p53 mutant cell lines, with minimal effect in p53 wild-type lines.
- The combination of MMC and UCN-01 increased DNA breaks and apoptosis in p53-defective A431 cells.
- UCN-01 abrogated MMC-induced S and G2 phase arrest in p53-defective cells, and to a lesser extent in p53 wild-type cells.
- In p53 wild-type cells, p21/WAF1 induction by MMC was delayed, and UCN-01's abrogation of arrest occurred before significant p53 response.
Conclusions:
- UCN-01 selectively potentiates mitomycin C (MMC) cytotoxicity in p53-defective cancer cells.
- The abrogation of cell cycle arrest by UCN-01 contributes to enhanced MMC efficacy in p53-mutant cancers.
- UCN-01 represents a potential new therapeutic strategy to improve MMC-based chemotherapy outcomes, especially for patients with p53-defective tumors.